Dr. Annie Pearl Im, MD

Dr. Im practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center.

Dr. Im's NPI, 1760675011, was assigned on August 21, 2007. Dr. Im graduated from Renaissance School of Medicine at Stony Brook University in 2006. Dr. Im holds Pennsylvania license MT189158.

Dr. Im's primary practice is UPMC Magee-Womens Hospital, at 300 Halket Street, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 641-4010.

Dr. Im's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania, part of University of Pittsburgh Medical Center. Dr. Im is also affiliated with UPMC Presbyterian. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Im to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Im practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Im's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Im is board certified in hematology by the American Board of Internal Medicine. Dr. Im is licensed in Pennsylvania.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Im treats.

CMS data shows 321 Medicare services from Dr. Im across 4 procedure codes in 2024, for 66 Medicare patients. Medicare paid $27,328 for them.

CMS counts 66 Medicare patients who saw Dr. Im in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Im's median patient age at 72, with 42% women.

In 2024, Dr. Im wrote 728 Medicare Part D claims for 61 patients. 74% of them were for generic drugs. CMS names the drug for 494 of them, across 21 drugs with 11 or more claims each, at $1,780,992 in total drug cost. In 2023, CMS named 760 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Im for performance year 2024, reported as part of a group. Dr. Im accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 56 papers to Dr. Im, published from 2009 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Leukemia, Myeloid, Acute. Dr. Im has published most often in Bone Marrow Transplant. Dr. Im's most frequent co-authors are Mounzer E. Agha, MD, Anastasios Raptis and Kathleen Anne Dorritie, MD.

Dmand AI links Dr. Im to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Graft vs Host Disease, Burkitt Lymphoma and Leukemia, Myeloid, Acute. University of Pittsburgh sponsors the most, 2.

CMS Open Payments shows 66 general payments to Dr. Im from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Sanofi and Genzyme US Companies paid the most, $31,835. It also lists 1 research payment totaling $122 in 2018.

Dr. Im graduated from Renaissance School of Medicine at Stony Brook University in 2006.

Dr. Im is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Highmark. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.